Selected Publications

Killarney, S.T.; Mesa, G.; Washart, R.; Mayro, B.; Dillon, K; Wardell, S.E.; Newlin, M.; Lu, M.; Abu Rmaileh, A.; Liu, N.; McDonnell, D.P.; Pendergast, A.M.; Wood, K.C.* (2024). PKN2 is a dependency of the mesenchymal-like cancer cell state, Cancer Discovery (In press).

Kelly, L.M.¶; Rutter, J.C.¶; Lin, K.H.¶; Ling, F.; Pasquer, H.; Nhat, D.H.; Namor, F.; Killarney, S.T.; Ang, H.X.; Arang, N.; Lombard, B.; Loew, D.; Brunel, L.; Carretero, E.; Verdie, P.; Amblard, M.; Fodil, S.; Huynh, T.; Sebert, M.; Ades, L.; Raffoux, E.; Fenouille, N.; Itzykson, R.; Forget, A.; Lobry, C.; Benajiba, L.; Martin, A.R.*; Wood, K.C.*; Puissant, A.* (2024). Targeting a lineage-specific PI3Kg/AKT signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule, Nature Cancer (In press). (¶Co-first authors; *Co-corresponding authors). [Pubmed][PDF]

Maltas, J.¶; Killarney, S.T.¶; Singleton, K.R.¶; Strobl, M.A.R.; Washart, R.; Wood, K.C.*; Wood, K.B.* (2024). Drug dependence in cancer is exploitable by optimally constructed treatment holidays, Nature Ecology & Evolution 8, 147-162. (¶Co-first authors; *Co-corresponding authors). [Pubmed][PDF]

Ang, H.X.; Sutiman, N.; Deng, X.L.; Liu, A.; Cerda-Smith, C.G.; Hutchinson, H.M.; Kim, H.; Bartelt, L.C.; Chen, Q.; Barrera, A.; Lin, J.; Shen, Z.; McDowell, I.C.; Reddy, T.E.; Nicchitta, C.V.*; Wood, K.C.* (2023). Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13, Proc. Natl. Acad. Sci. USA 120, e2221448120 (*Co-corresponding authors). [Pubmed][PDF]

Killarney, S.T.; Washart, R.; Soderquist, R.S.; Hoj, J.P.; Lebhar, J.; Lin, K.H.; Wood, K.C.* (2023). Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis, Nature Communications 14, 1399. [Pubmed][PDF]

Lin, K.H.¶; Rutter, J.C.¶; Xie, A.; Killarney, S.T.; Vaganay, C.; Benaksas, C.; Ling, F.; Sodaro, G.; Meslin, P.A.; Bassil, C.F.; Fenouille, N.; Hoj, J.P.; Washart, R.; Ang, H.X.; Cerda-Smith, C.G.; Chaintreuil, P.; Jacquel, A.; Auberger, P.; Forget, A.; Itzykson, R.; Lu, M.; Lin, J.; Pierobon, M.; Sheng, Z.; Li, X.; Chilkoti, A.; Owzar, K.; Rizzieri, D.A.; Pardee, T.S.; Benajiba, L.; Petricoin, E.; Puissant, A.*; Wood, K.C.* (2022). P2RY2-AKT activation is a critical actionable consequence of nuclear export inhibition in acute myeloid leukemia, Nature Cancer 3, 837-851. (¶Co-first authors; *Co-corresponding authors). [Pubmed][PDF]

Ali, M.; Lu, M.; Ang., H.X.; Soderquist, R.S.; Eyler, C.E.; Hutchinson, H.M.; Glass, C.; Bassil, C.F.; Lopez, O.M.; Kerr, D.L.; Falcon, C.J.; Yu, H.A.; Hata, A.N.; Blakely, C.M.; McCoach, C.E.; Bivona, T.G.; Wood, K.C. (2022). Small molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells, Science Translational Medicine 14, eabc7480. [Pubmed][PDF]

Yellen, B.B.*; Zawistowski, J.S.; Czech, E.A.; Sanford, C.I.; SoRelle, E.D.; Luftig, M.A.; Forbes, Z.G.; Wood, K.C.*; Hammerbacher, J.* (2021) Massively parallel quantification of phenotypic heterogeneity in single cell drug responses, Science Advances 7, eabf9840. (*Co-corresponding authors) [Pubmed][PDF]

Su, A.¶; Ling, F.¶; Vaganay, C.; Sodaro, G.; Benaksas, C.; Del Bello, R.; Forget, A.; Benajiba, L.; Pardieu, B.; Lin, K.H.; Rutter, J.C.; Bassil, C.F.; Fortin, G.; Pasanisi, J.; Antony-Debre, I.; Alexe, G.; Benoist, J.-F.; Pruvost, A.; Pikman, Y.; Qi, J.; Schlageter, M.H.; Micol, J.B.; Roti, G.; Cluzeau, T.; Dombret, H.; Preudhomme, C.; Fenouille, N.; Golan, H.M.; Stegmaier, K.; Lobry, C.*; Wood, K.C.*; Itzykson, R.*; Puissant, A.* (2020). The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies, Cancer Discovery 10, 1894-1911. (¶Co-first authors; *Co-senior authors) [Pubmed][PDF]

Lin, K.H.¶; Rutter, J.C.¶; Xie, A.; Pardieu, B.; Winn. E.T.; Dal Bello, R.; Forget, A.; Itzykson, R.; Ahn, Y.-R.; Dai, Z.; Sobhan, R.T.; Anderson, G.R.; Singleton, K.R.; Decker, A.E.; Winter, P.S.; Locasale, J.W.; Crawford, L.; Puissant, A.*; Wood, K.C.* (2020). Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer, Nature Genetics 52, 408-417. (¶co-first authors; *co-corresponding authors) [Pubmed][PDF]

Manzari, M.T.; Anderson, G.R.; Lin, K.H.; Soderquist, R.S.; Cakir, M.; Zhang, M.; Moore, C.E.; Skelton, R.N.; Fevre, M.; Li, X.; Bellucci, J.J.; Wardell, S.E.; Costa, S.A.; Wood, K.C.*; Chilkoti, A.* (2019). Genomically informed small molecule drugs overcome resistance to a sustained release formulation of an engineered death receptor agonist in patient-derived tumor models, Science Advances 5, eaaw9162. (*Co-corresponding authors) [Pubmed][PDF]

Lin, K.H.¶; Xie, A.¶; Rutter, J.C.; Ahn, Y.; Lloyd-Cowden, J.M.; Nichols, A.G.; Soderquist, R.S.; Koves, T.R.; Muoio, D.; MacIver, N.J.; Lamba, J.; Pardee, T.S.; McCall, C.M.; Rizzieri, D.A.; Wood, K.C. (2019). Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity, Cell Metabolism 29, 1217. (¶Co-first authors; journal cover article) [Pubmed][PDF]

Ding, Y.; Huang, D.; Chen, R.; Gong, C.; Sui, P.; Lin, K.H.; Yuan, L.; Xiang, H.; Chen, J.; Yin, T.; Wang, Q.F.; Alexander, P.D.; Song, E.W.; Li, Q.-J.; Wood, K.C.*; Wang, X.F.* (2018). Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers, Nature Communications 9, 4274. (*Co-corresponding authors) [Pubmed][PDF]

Soderquist, R.S.; Crawford, L.; Liu, E.; Lu, M.; Agarwal, A.; Anderson, G.R.; Lin, K.H.; Winter, P.S.; Cakir, M.; Wood, K.C. (2018). Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity, Nature Communications 9, 3513. [Pubmed][PDF]

Anderson, G.R.; Wardell, S.E.; Cakir, M.; Yip, C.; Ahn, Y.; Ali, M.; Yllanes, A.P.; Chao, C.A.; McDonnell, D.P.; Wood, K.C. (2018). Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors, Nature Communications 9, 1677. [Pubmed][PDF]

Singleton, K.R.¶; Crawford, L.¶; Tsui, E.; Manchester, H.E.; Maertens, O.; Liu, X.; Liberti, M.V.; Magpusao, A.N.; Stein, E.M.; Tingley, J.P.; Frederick, D.T.; Boland, G.M.; Flaherty, K.T.; McCall, S.J.; Krepler, C.; Sproesser, K.; Herlyn, M.; Adams, D.J.; Locasale, J.W.; Cichowski, K.; Mukherjee, S.; Wood, K.C. (2017). Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence, Cell Reports 21, 2796-2812. (¶Co-first authors) [Pubmed][PDF]

Anderson, G.R.¶; Winter, P.S.¶; Lin, K.H.; Nussbaum, D.P.; Cakir, M.; Stein, E.M.; Soderquist, R.; Crawford, L.; Leeds, J.C.; Newcomb, R.; Stepp, P.; Yip, C.; Wardell, S.E.; Tingley, J.P.; Ali, M.; Xu, M.; Ryan, M.; McCall, S.J.; McRee, A.; Counter, C.M.; Der, C.J.; Wood, K.C. (2017). A landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution, Cell Reports 20, 999-1015. (¶Co-first authors) [Pubmed][PDF]

Ali, M.¶; Kaltenbrun, E.¶; Anderson, G.R.¥; Stephens, S.J.¥; Arena, S.; Bardelli, A.; Counter, C.M.*; Wood, K.C.* (2017). Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance, Nature Communications 8, 15617. (¶Co-first authors, ¥Co-second authors, *Corresponding authors) [PubMed][PDF]

Anderson, G.R.; Wardell, S.E.; Cakir, M.; Crawford, L.; Leeds, J.C.; Nussbaum, D.N.; Shankar, P.S.; Soderquist, R.S.; Stein, E.M.; Tingley, J.P.; Winter, P.S.; Zeiser-Misenheimer, E.K.; Alley, H.M.; Yllanes, A.; Haney, V.; Blackwell, K.L.; McCall, S.J.; McDonnell, D.P.; Wood, K.C. (2016). PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation, Science Translational Medicine 8, 369ra175. [Pubmed][PDF]

Martz, C.A.¶; Ottina, K.A.¶; Singleton, K.S.¶; Jasper, J.S.; Wardell, S.E.; Peraza-Penton, A.; Anderson, G.R.; Winter, P.S.; Wang, T.; Alley, H.M.; Kwong, L.N.; Cooper, Z.A.; Tetzlaff, M.; Chen, P.-L.; Rathmell, J.C.; Flaherty, K.T.; Wargo, J.A.; McDonnell, D.M.; Sabatini, D. M.*; Wood, K.C.* (2014). Systematic identification of signaling pathways with potential to confer anticancer drug resistance, Science Signaling 7, ra121. (¶Co-first authors, *Co-corresponding authors; journal cover article) [Pubmed][PDF][Podcast]

Winter, P.S.; Sarosiek, K.A.; Lin, K.H.; Meggendorfer, M.; Schnittger, S.; Letai, A.; Wood, K.C. (2014). RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis, Science Signaling 7, ra122. [Pubmed][PDF][Podcast][Table S4]

Wood, K.C.; Konieczkowski, D.J.; Johannessen, C.M.; Boehm, J.S.; Tamayo, P.; Botvinnik, O.B.; Mesirov, J.P.; Hahn, W.C.; Root, D.E.; Garraway, L.A.; Sabatini, D.M. (2012). MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma, Science Signaling 5, rs4 (journal cover article). [Pubmed][PDF]